SkylineDx, a leading diagnostics innovator specializing in molecular diagnostics for oncology, inflammatory, and infectious diseases, has announced significant findings from a Danish validation study recently published in the Journal of Surgical Oncology. This study confirms that SkylineDx’s Merlin Assay, also known as CP-GEP, can accurately identify cutaneous melanoma patients, particularly […]
Featured News
Texas Cardiac Arrhythmia Institute First in U.S. to Implant Leadless Heart Failure Therapy Device
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center electrophysiologists have achieved a significant milestone by being the first medical team in the US to implant a novel, FDA-approved leadless device intended to provide cardiac resynchronization therapy to patients with heart failure. This therapy plays a vital role […]
Saluda Medical Rolls Out EVA Nationwide: A Breakthrough in Spinal Cord Stimulation Treatment
Saluda Medical, Inc., a leader in the advancement of neuromodulation technologies aimed at improving the lives of patients with chronic neurological disorders, has formally declared EVA’s full-scale commercial availability, its most recent advancements in sensing technology, all around the United States. This comes after EVA was approved by the US […]
FDA Grants Orphan Drug Designation to Amphix Bio’s Spinal Cord Injury Treatment
Amphix Bio, an innovative pre-clinical stage biotechnology company, has announced that its lead therapeutic candidate, AMFX-200, has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of acute spinal cord injury (SCI). This condition, which affects approximately 18,000 individuals annually in the United States, often […]
Microcurrent Therapy From Berlin Heals Shows Disease-Modifying Potential in Heart Failure Patients
Berlin Heals, an innovator in the field of bioelectric medicine aimed at treating heart failure, has announced the publication of a groundbreaking peer-reviewed study in the ESC Heart Failure journal. The study, titled “Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study,” highlights the […]
FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance
FinThrive, Inc., a leading healthcare revenue management software-as-a-service (SaaS) provider, will have a significant presence at the 2025 Healthcare Financial Management Association (HFMA) Annual Conference, which will take place June 22-25 in Denver, Colorado. With high-profile speaking engagements, live demonstrations of cutting-edge solutions, and Agentic AI-driven innovation, FinThrive will showcase how its revenue cycle […]
NeuralCure AI Launches the First Diagnostic & Digital Twin OS for Preventative Care Clinics
NeuralCure AI today announced the official launch of its groundbreaking Diagnostic & Digital Twin Operating System, the first infrastructure platform purpose-built for the exploding preventative, regenerative, and patient-led healthcare market. As millions of Americans take control of their health, ordering their own labs and imaging, using AI to self-navigate symptoms, […]
Outcomes4Me Acquires Germany’s Mika Health App to Accelerate AI-Driven Patient Empowerment Globally
Outcomes4Me Inc., the developer of the leading, direct-to-patient, AI-driven platform transforming the cancer-care experience, announced today that its German affiliate Outcomes4Me Germany GmbH has acquired the assets associated with the Mika Health app from Berlin-based Fosanis GmbH. The Mika app has served over 100,000 cancer patients globally, and is a clinically […]
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech’s expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein […]
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options […]
